Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 ...

A pharmacodynamic study sponsored by Purdue Pharma L.P. ("Purdue"), conducted in healthy moderately experienced opioid users (n = 24) using an opioid induced respiratory depression (OIRD) model, found ...

GPs are calling on the Victorian Government to follow the lead of other states and territories and introduce needle-free influenza vaccinations for ...

GPs are calling on the Victorian Government to follow the lead of other states and territories and introduce needle-free influenza vaccinations for ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of ...

Topline results were announced from a phase 3 trial investigating intranasal carbetocin for the treatment of hyperphagia in Prader-Willi syndrome.

Instead of stabbing yourself, or someone else, in the thigh with a needle to deliver a dose of adrenaline to counter anaphylactic shock, would it not be easier to use a nasal spray instead?

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 grant ...

Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biome ...

A large trial reveals that boosting testosterone does not influence men's economic preferences, challenging previous studies linking the hormone to behavior.

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...

Acadia Pharmaceuticals said on Wednesday that its experimental therapy to treat a rare metabolic condition failed to meet the main goal in a late-stage study.